VIR · Insider Trading
Vir Biotechnology, Inc. Common Stock
Every open-market purchase and sale reported by VIR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-12 | Robert J More | Director | J | — | — |
| 2026-06-10 | Timothy Coughlin | Director | A | +16,000 | — |
| 2026-06-02 | Janet Napolitano | Director | Sell | −3,200 | −$30.24K |
| 2026-06-02 | Brent Sabatini | SVP, Chief Accounting Officer | Sell | −379 | −$3.58K |
| 2026-05-28 | Jeffrey S. Hatfield | Director | A | +8,000 | — |
| 2026-05-28 | Norbert W Bischofberger | Director | A | +8,000 | — |
| 2026-05-28 | Charles Elliott Sigal | Director | A | +8,000 | — |
| 2026-05-28 | Ramy Farid | Director | A | +8,000 | — |
| 2026-05-28 | Robert J More | Director | A | +8,000 | — |
| 2026-05-28 | Janet Napolitano | Director | A | +8,000 | — |
| 2026-05-04 | Vicki L Sato | Director | Sell | −22,000 | −$221.03K |
| 2026-04-07 | Marianne De Backer | President and CEO | Sell | −72,559 | −$664.35K |
| 2026-04-02 | Vicki L Sato | Director | Sell | −22,000 | −$199.62K |
| 2026-03-24 | Brent Sabatini | SVP, Chief Accounting Officer | Sell | −7,711 | −$70.32K |
| 2026-03-23 | Jason O'Byrne | EVP & Chief Financial Officer | J | — | — |
| 2026-03-03 | Vicki L Sato | Director | Sell | −22,000 | −$209.18K |
| 2026-02-26 | Mark Eisner | EVP and Chief Medical Officer | Sell | −3,505 | −$33.95K |
| 2026-02-26 | Jason O'Byrne | EVP & Chief Financial Officer | Sell | −1,634 | −$15.58K |
| 2026-02-26 | Marianne De Backer | Chief Executive Officer | Sell | −14,762 | −$140.72K |
| 2026-02-26 | Vicki L Sato | Director | MIXED | — | −$350.44K |
| 2026-02-26 | Brent Sabatini | SVP, Chief Accounting Officer | Sell | −1,430 | −$13.63K |
| 2026-02-26 | Vanina de Verneuil | EVP, General Counsel, Corp Sec | Sell | −16,817 | −$164.25K |
| 2026-02-24 | Brent Sabatini | SVP, Chief Accounting Officer | MIXED | +23,171 | −$13.63K |
| 2026-02-24 | Vanina de Verneuil | EVP, General Counsel, Corp Sec | MIXED | +50,555 | −$33.13K |
| 2026-02-24 | Jason O'Byrne | EVP & Chief Financial Officer | MIXED | +52,911 | −$15.57K |
| 2026-02-24 | Marianne De Backer | Chief Executive Officer | MIXED | +265,961 | −$141.89K |
| 2026-02-24 | Mark Eisner | EVP and Chief Medical Officer | MIXED | +52,911 | −$15.57K |
| 2026-02-18 | Brent Sabatini | SVP, Chief Accounting Officer | Sell | −1,530 | −$11.92K |
| 2026-02-03 | Vicki L Sato | Director | Sell | −22,000 | −$169.67K |
| 2026-01-05 | Vicki L Sato | Director | Sell | −22,000 | −$130.38K |
| 2025-12-03 | SOFTBANK VISION FUND (AIV M1) L.P. | 10%+ Owner | Sell | −575,562 | −$3.44M |
| 2025-12-02 | Vicki L Sato | Director | Sell | −22,000 | −$132.07K |
| 2025-12-01 | SOFTBANK VISION FUND (AIV M1) L.P. | 10%+ Owner | Sell | −568,293 | −$3.64M |
| 2025-11-26 | SOFTBANK VISION FUND (AIV M1) L.P. | 10%+ Owner | Sell | −1,391,322 | −$8.72M |
| 2025-11-18 | Jason O'Byrne | EVP & Chief Financial Officer | Sell | −6,799 | −$37.78K |
| 2025-11-07 | Vanina de Verneuil | EVP, General Counsel, Corp Sec | Sell | −2,385 | −$12.31K |
| 2025-11-04 | Vanina de Verneuil | EVP and General Counsel | Sell | −1,365 | −$8.00K |
| 2025-11-04 | Vicki L Sato | Director | Sell | −22,000 | −$124.05K |
| 2025-10-30 | SB INVESTMENT ADVISERS (UK) LTD | 10%+ Owner | Sell | −73,659 | −$478.96K |
| 2025-10-28 | SB INVESTMENT ADVISERS (UK) LTD | 10%+ Owner | Sell | −339,297 | −$2.04M |
| 2025-10-24 | SOFTBANK VISION FUND (AIV M1) L.P. | 10%+ Owner | Sell | −895,947 | −$5.44M |
| 2025-10-22 | SOFTBANK VISION FUND (AIV M1) L.P. | 10%+ Owner | Sell | −990,630 | −$6.17M |
| 2025-10-17 | SB INVESTMENT ADVISERS (UK) LTD | 10%+ Owner | Sell | −88,545 | −$538.69K |
| 2025-10-14 | SB INVESTMENT ADVISERS (UK) LTD | 10%+ Owner | Sell | −754,080 | −$4.63M |
| 2025-10-09 | SOFTBANK VISION FUND (AIV M1) L.P. | 10%+ Owner | Sell | −1,615,125 | −$9.67M |
| 2025-10-07 | SOFTBANK VISION FUND (AIV M1) L.P. | 10%+ Owner | Sell | −1,572,891 | −$8.77M |
| 2025-10-02 | Vicki L Sato | Director | Sell | −22,000 | −$128.40K |
| 2025-09-03 | Vicki L Sato | Director | Sell | −22,000 | −$109.81K |
| 2025-08-04 | Vicki L Sato | Director | Sell | −22,000 | −$109.70K |
| 2025-07-17 | Mark Eisner | EVP and Chief Medical Officer | Sell | −10,382 | −$56.79K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| SB INVESTMENT ADVISERS (UK) LTD | 10%+ Owner | 14,574,083 | $151.13M |
| SOFTBANK VISION FUND (AIV M1) L.P. | 10%+ Owner | 13,728,924 | $142.37M |
| George A Scangos | Director | 1,296,509 | $13.44M |
| Vicki L Sato | Director | 1,078,391 | $11.18M |
| Marianne De Backer | President and CEO | 1,001,263 | $10.38M |
| Robert J More | Director | 558,573 | $5.79M |
| Jason O'Byrne | EVP & Chief Financial Officer | 162,615 | $1.69M |
| Mark Eisner | EVP and Chief Medical Officer | 155,913 | $1.62M |
| Ann M. Hanly | EVP & Chief Technology Officer | 117,912 | $1.22M |
| Vanina de Verneuil | EVP, General Counsel, Corp Sec | 112,982 | $1.17M |
| Brent Sabatini | SVP, Chief Accounting Officer | 61,902 | $641.92K |
| Charles Elliott Sigal | Director | 49,806 | $516.49K |
| Jeffrey S. Hatfield | Director | 39,806 | $412.79K |
| Norbert W Bischofberger | Director | 32,000 | $331.84K |
| Ramy Farid | Director | 32,000 | $331.84K |
| Saira Ramasastry | Director | 22,619 | $234.56K |
| Janet Napolitano | Director | 21,216 | $220.01K |
| Timothy Coughlin | Director | 8,000 | $82.96K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VIR quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.